Emergent BioSolutions, Inc. (EBS)
6.11
+0.20
(+3.38%)
USD |
NYSE |
Aug 31, 16:00
6.11
0.00 (0.00%)
After-Hours: 20:00
Emergent BioSolutions Cash from Operations (TTM) : 97.70M for June 30, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 97.70M |
| March 31, 2026 | 148.00M |
| December 31, 2025 | 170.60M |
| September 30, 2025 | 13.00M |
| June 30, 2025 | 169.00M |
| March 31, 2025 | 110.10M |
| December 31, 2024 | 58.70M |
| September 30, 2024 | 170.70M |
| June 30, 2024 | 77.00M |
| March 31, 2024 | -84.90M |
| December 31, 2023 | -206.30M |
| September 30, 2023 | -145.60M |
| June 30, 2023 | -279.60M |
| March 31, 2023 | -180.80M |
| December 31, 2022 | -34.10M |
| September 30, 2022 | 201.20M |
| June 30, 2022 | 291.90M |
| March 31, 2022 | 277.80M |
| December 31, 2021 | 320.20M |
| September 30, 2021 | 237.20M |
| June 30, 2021 | 325.70M |
| March 31, 2021 | 483.30M |
| December 31, 2020 | 536.00M |
| September 30, 2020 | 413.00M |
| June 30, 2020 | 304.70M |
| Date | Value |
|---|---|
| March 31, 2020 | 141.00M |
| December 31, 2019 | 188.00M |
| September 30, 2019 | -99.86M |
| June 30, 2019 | 77.21M |
| March 31, 2019 | 147.59M |
| December 31, 2018 | 41.80M |
| September 30, 2018 | 286.52M |
| June 30, 2018 | 146.06M |
| March 31, 2018 | 165.48M |
| December 31, 2017 | 208.14M |
| September 30, 2017 | 120.01M |
| June 30, 2017 | 88.10M |
| March 31, 2017 | 52.99M |
| December 31, 2016 | 53.49M |
| September 30, 2016 | 65.73M |
| June 30, 2016 | 168.89M |
| March 31, 2016 | 152.50M |
| December 31, 2015 | 44.46M |
| September 30, 2015 | 93.21M |
| June 30, 2015 | 67.37M |
| March 31, 2015 | 75.69M |
| December 31, 2014 | 112.32M |
| September 30, 2014 | 69.14M |
| June 30, 2014 | 50.34M |
| March 31, 2014 | 72.35M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Exelixis, Inc. | 1.183B |
| Capricor Therapeutics, Inc. | -104.00M |
| ADMA Biologics, Inc. | 136.72M |
| Akebia Therapeutics, Inc. | 41.55M |
| Arcutis Biotherapeutics, Inc. | 39.31M |